MedTrace Logo

The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody

NCT04466267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-07-10

No results posted yet for this study

Summary

Establishing the genetic map of primary and secondary resistance of Chinese wild RAS colorectal cancer received anti-EGFR treatment through tissues and peripheral blood NGS testing. Combination genetic data with clinical characteristics, prognosis and treatment data to explore the molecular mechanism of resistance of anti-EGFR-antibody.

Conditions

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Ying Jin, MD.,PhD · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2020-03-01
Completion
2020-07-04

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04466267 on ClinicalTrials.gov